<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333385</url>
  </required_header>
  <id_info>
    <org_study_id>01648</org_study_id>
    <nct_id>NCT00333385</nct_id>
  </id_info>
  <brief_title>Continuous Versus Short Infusions of Ceftazidime in Cystic Fibrosis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vaincre la Mucoviscidose</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baxter Healthcare Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Association Nationale pour les Traitements A Domicile, les Innovations et la Recherche</source>
  <brief_summary>
    <textblock>
      The aim of this trial was to compare the safety and efficacy of courses of tobramycin and
      ceftazidime, administered intravenously as either thrice daily short infusions or 24 h
      continuous infusion, in cystic fibrosis patients with acute exacerbation of chronic pulmonary
      PA infection. In conventional treatment regimens, ceftazidime is administered in the form of
      thrice daily short infusions, but pharmacodynamic considerations suggest that continuous
      infusion could be more effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each patient received two successive IV antibiotic courses during a period of pulmonary
      exacerbation. One of these courses was delivered as thrice daily 30-minute infusions of
      ceftazidime in 100 ml of 0.9% sodium chloride, and the other was delivered as a continuous
      infusion of ceftazidime in 230 ml of 0.9% sodium chloride, over 23 hours. The daily dose of
      ceftazidime was 200 mg/kg, with a maximum dose of 12 g. For ceftazidime continuous infusion,
      a loading dose of 60 mg/kg (maximum 2 g) was used. All patients also received tobramycin (10
      mg/kg), in the form of one 30-minute infusion per day. Portable devices were used: Intermate®
      SV 200 (Baxter) for the 30-minute short infusions of ceftazidime and tobramycin, Infusor®
      LV10 (Baxter) for continuous infusion of ceftazidime.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>October 2001</start_date>
  <completion_date>April 2004</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in forced expiratory volume in 1s (FEV1) between the beginning and the end of the IV antibiotic course, expressed as a percentage of the predicted normal value</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>the interval between 2 successive IV antibiotic courses</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>quality of life scores</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sputum collected at the beginning and the end of each antibiotic course</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma ceftazidime concentration at steady state (Css) for ceftazidime continuous infusion, and before (C trough), 30 minutes (Cmax) and 4 hours after (C4) the beginning of ceftazidime short infusion</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein, leukocytes and hepatic enzymes levels at the beginning and the end of each IV antibiotic course</measure>
  </secondary_outcome>
  <enrollment>120</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Pseudomonas Aeruginosa</condition>
  <condition>Pulmonary Exacerbation</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ceftazidime</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with cystic fibrosis older than 8 years

          -  with chronic Pseudomonas aeruginosa infection of the respiratory tract

          -  with at least 2 courses of IV antibiotic in the year before enrolment

          -  at the time of a pulmonary exacerbation

        Exclusion Criteria:

          -  allergy to ceftazidime or tobramycin

          -  bronchial colonization with Burkholderia cepacia

          -  renal impairment

          -  history of lung transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dominique Hubert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier Dr Schaffner</name>
      <address>
        <city>Lens</city>
        <zip>62307</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Albert Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Jeanne de Flandre</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sainte Marguerite</name>
      <address>
        <city>Marseille</city>
        <zip>13000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des hopitaux de paris, Hopital Trousseau</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hopitaux de Paris, Hopital Cochin</name>
      <address>
        <city>Paris</city>
        <zip>75014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hopitaux de Paris, Hopital Necker</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assistance Publique des Hopitaux de Paris, Hopital Robert Debré</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sud</name>
      <address>
        <city>Rennes</city>
        <zip>35056</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Héliomarin</name>
      <address>
        <city>Roscoff</city>
        <zip>29684</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Hautepierre</name>
      <address>
        <city>Strasbourg</city>
        <zip>67000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital de Brabois</name>
      <address>
        <city>Vandoeuvre-les-Nancy</city>
        <zip>54511</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2001</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 2, 2006</study_first_submitted>
  <study_first_submitted_qc>June 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2006</study_first_posted>
  <last_update_submitted>June 2, 2006</last_update_submitted>
  <last_update_submitted_qc>June 2, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2006</last_update_posted>
  <keyword>Ceftazidime</keyword>
  <keyword>Continuous infusion</keyword>
  <keyword>Antibiotic course</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ceftazidime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

